Read More Analyst Ratings News Price Target Morgan Stanley Maintains Overweight on 2seventy bio, Lowers Price Target to $28 By Benzinga Newsdesk January 24, 9:06 AM Morgan Stanley analyst Matthew Harrison maintains 2seventy bio (NASDAQ:TSVT) with a Overweight and lowers the price target from $29 to $28. TSVT
Read More Government M&A Media News Regulations Tech Microsoft Modifies Activision Blizzard Purchase After UK Regulatory Setback: Report By Anusuya Lahiri August 22, 8:09 AM Microsoft Corp (NASDAQ: MSFT) recently presented a revised proposal to purchase Activision Blizzard Inc (NASDAQ: ATVI) after U.K. ATVI
Read More Analyst Ratings News Penny Stocks Price Target Reiteration Trading Ideas c By Anusuya Lahiri August 24, 1:35 PM Benchmark analyst Fawne Jiang maintained Grab Holdings Limited (NASDAQ: GRAB) with a Buy and raised the GRAB
Read More Earnings Earnings Outlook For Allogene Therapeutics By Benzinga Insights November 1, 3:02 PM Allogene Therapeutics (NASDAQ:ALLO) is set to give its latest quarterly earnings report on Thursday, 2023-11-02. Here’s what investors… ALLO